Table 7 TGLS in healthy controls and patients with or without drug adjustment
Healthy controls (n = 30) | Patients without drug adjustment (n = 22) | Patients received drug adjustment (n = 28) | ||||
|---|---|---|---|---|---|---|
Baseline echo | Follow-up echo | Baseline echo | Follow-up echo | Baseline echo | Follow-up echo | |
LVEF, % | 64.3 ± 6.4 | 65.6 ± 5.7 | 70.8 ± 6.1 | 69.6 ± 7.3 | 72.7 ± 5.4 | 73.7 ± 6.5 |
Resting LVOT gradient, mmHg | 7.8 ± 1.6 | 7.0 ± 2.1 | 18.2 (6.1—30.3) | 18.0 (6.0—30.0) | 70.0 (47.0—90.0) | 40.0 (17.0—68.0) * |
Global LS, % | -20.3 ± 6.84 | -22.6 ± 5.49 | -12.3 ± 7.87 | -12.3 ± 8.79 | -13.7 ± 10.10 | -14.7 ± 9.70 |
TGLS basal, % | −2.17 ± 1.66 | −2.58 ± 1.03 | -1.22 ± 2.10 | -1.19 ± 2.70 | -1.01 ± 2.14 | -1.71 ± 2.98** |
TGLS mid, % | −3.58 ± 2.29 | −3.27 ± 2.88 | -3.28 ± 2.48 | -2.98 ± 2.39 | -2.72 ± 2.50 | -3.31 ± 2.64** |
TGLS apex, % | −10.54 ± 3.20 | −11.10 ± 4.21 | -9.9 ± 3.99 | -9.5 ± 3.75 | -9.8 ± 4.11 | -10.21 ± 3.79 |
Number of segments with abnormal TGLS | 6 | 8 | 72 | 79 | 145 | 84*** |